- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles
- Instablogs1 new
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
MRK Market Currents
more »
-
Friday 4:28 PM Shares of Amylin Pharmaceuticals (AMLN +8.4%) finished markedly higher on reports that the company, which is on the sales block, was already receiving bids from Sanofi (SAN) and Merck (MRK) in excess of $25 per share.
1 Comment[Healthcare, On the Move, M&A]
- Monday 2:30 PM Merck (MRK -0.5%) says its follow-up study on an AIDS vaccine trial that had to be stopped early has confirmed the worst fears of researchers: The vaccine made it more likely, not less, that some men would become infected with H.I.V. [Healthcare]
MRK in Focus
more »
MRK Related Articles
more »
MRK News
more »
-
at MarketWatch.com (Mon, 12:21PM)
-
at MarketWatch.com (May 16, 2012)
-
at MarketWatch.com (May 15, 2012)
-
at MarketWatch.com (May 14, 2012)
-
at CNBC.com (May 7, 2012)
MRK Press Releases and Filings
more »
-
Business Wire (Dec 6, 2011)
MRK Latest Transcript
more »
-
Fri, Apr 27
MRK Cramer
more »
MRK Instablog posts
more »
MRK vs. ETF Alternatives
Company Description
On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More